Harvard Bioscience (HBIO) Other Non-Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Non-Current Liabilities data on file, last reported at $1.1 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.1 million, down 19.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 19.07% YoY), and the FY2025 annual result was $1.3 million, up 4.22% from the prior year.
• Other Non-Current Liabilities retreated to $1.1 million in Q1 2026 per HBIO's latest filing, from $1.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $1.6 million in Q2 2024 and troughed at $418000.0 in Q2 2022.
• A 5-year average of $1.2 million and a median of $1.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 83.53% in 2022, then jumped 150.24% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $1.0 million in 2022, then jumped by 46.72% to $1.5 million in 2023, then retreated by 14.97% to $1.3 million in 2024, then climbed by 4.22% to $1.3 million in 2025, then decreased by 12.39% to $1.1 million in 2026.
• Business Quant data shows HBIO's Other Non-Current Liabilities at $1.1 million in Q1 2026, $1.3 million in Q4 2025, and $1.5 million in Q3 2025.